PDCD1 and neoplasm: In fact, the KEYNOTE-024 results demonstrate that treatment with pembrolizumab (an anti-PD-1 inhibitor) produces significantly longer PFS and OS and fewer adverse events when there is PD-L1 expression on at least 50% of tumor cells in advanced NSCLC [67].